Investors in Apeloa PharmaceuticalLtd (SZSE:000739) Have Seen Respectable Returns of 69% Over the Past Five Years
Investors in Apeloa PharmaceuticalLtd (SZSE:000739) Have Seen Respectable Returns of 69% Over the Past Five Years
When we invest, we're generally looking for stocks that outperform the market average. Buying under-rated businesses is one path to excess returns. For example, the Apeloa Pharmaceutical Co.,Ltd (SZSE:000739) share price is up 61% in the last 5 years, clearly besting the market return of around 17% (ignoring dividends).
當我們投資時,我們通常是在尋找表現超過市場平均水平的股票。收購被低估的企業是獲得超額回報的一種途徑。例如,Apeloa Pharmaceutical Co., Ltd(深圳證券交易所股票代碼:000739)的股價在過去5年中上漲了61%,顯然超過了約17%的市場回報率(不計股息)。
With that in mind, it's worth seeing if the company's underlying fundamentals have been the driver of long term performance, or if there are some discrepancies.
考慮到這一點,值得一看公司的基本面是否是長期業績的驅動力,或者是否存在一些差異。
There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).
不可否認,市場有時是有效的,但價格並不總是能反映潛在的業務表現。研究市場情緒如何隨着時間的推移而變化的一種方法是研究公司股價與其每股收益(EPS)之間的相互作用。
During five years of share price growth, Apeloa PharmaceuticalLtd achieved compound earnings per share (EPS) growth of 21% per year. The EPS growth is more impressive than the yearly share price gain of 10% over the same period. So one could conclude that the broader market has become more cautious towards the stock.
在五年的股價增長中,Apeloa PharmaceuticalLTD實現了每年21%的複合每股收益(EPS)增長。每股收益的增長比同期10%的年度股價增長更令人印象深刻。因此,人們可以得出結論,整個市場對該股變得更加謹慎。
The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers).
該公司的每股收益(隨着時間的推移)如下圖所示(點擊查看確切數字)。
![earnings-per-share-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240521/0-bb039ca0b58ba9b8d1392e2b2935f3d8-0-bf629094a3b379ba116093a5fb461ca5.png/big)
We're pleased to report that the CEO is remunerated more modestly than most CEOs at similarly capitalized companies. But while CEO remuneration is always worth checking, the really important question is whether the company can grow earnings going forward. Before buying or selling a stock, we always recommend a close examination of historic growth trends, available here..
我們很高興地向大家報告,首席執行官的薪水比資本相似公司的大多數首席執行官都要適中。但是,儘管首席執行官的薪酬總是值得檢查的,但真正重要的問題是公司未來能否增加收益。在買入或賣出股票之前,我們始終建議仔細研究歷史增長趨勢,可在此處查閱。
What About Dividends?
分紅呢?
When looking at investment returns, it is important to consider the difference between total shareholder return (TSR) and share price return. Whereas the share price return only reflects the change in the share price, the TSR includes the value of dividends (assuming they were reinvested) and the benefit of any discounted capital raising or spin-off. So for companies that pay a generous dividend, the TSR is often a lot higher than the share price return. We note that for Apeloa PharmaceuticalLtd the TSR over the last 5 years was 69%, which is better than the share price return mentioned above. The dividends paid by the company have thusly boosted the total shareholder return.
在考慮投資回報時,重要的是要考慮兩者之間的區別 股東總回報 (TSR) 和 股價回報。儘管股價回報率僅反映股價的變化,但股東總回報率包括股息的價值(假設已進行再投資)以及任何折扣融資或分拆的收益。因此,對於支付豐厚股息的公司來說,股東總回報率通常遠高於股價回報率。我們注意到,Apeloa PharmaceuticalLTD在過去5年的股東總回報率爲69%,好於上述股價回報率。因此,該公司支付的股息提高了股息 總 股東回報。
A Different Perspective
不同的視角
We regret to report that Apeloa PharmaceuticalLtd shareholders are down 19% for the year (even including dividends). Unfortunately, that's worse than the broader market decline of 8.7%. However, it could simply be that the share price has been impacted by broader market jitters. It might be worth keeping an eye on the fundamentals, in case there's a good opportunity. Longer term investors wouldn't be so upset, since they would have made 11%, each year, over five years. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. It's always interesting to track share price performance over the longer term. But to understand Apeloa PharmaceuticalLtd better, we need to consider many other factors. To that end, you should be aware of the 1 warning sign we've spotted with Apeloa PharmaceuticalLtd .
我們遺憾地報告,Apeloa PharmaceuticalLTD的股東今年下跌了19%(甚至包括股息)。不幸的是,這比整個市場8.7%的跌幅還要嚴重。但是,可能只是股價受到了更廣泛的市場緊張情緒的影響。如果有很好的機會,可能值得關注基本面。長期投資者不會那麼沮喪,因爲他們本可以在五年內每年賺11%。如果基本面數據繼續顯示長期可持續增長,那麼當前的拋售可能是一個值得考慮的機會。長期跟蹤股價表現總是很有意思的。但是,要更好地了解Apeloa PharmaceuticalLTD,我們需要考慮許多其他因素。爲此,你應該注意我們在Apeloa PharmaceuticalLTD身上發現的1個警告信號。
But note: Apeloa PharmaceuticalLtd may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).
但請注意:Apeloa PharmaceuticalLTD可能不是最值得購買的股票。因此,來看看這份過去盈利增長(以及進一步增長預測)的有趣公司的免費清單。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
請注意,本文引用的市場回報反映了目前在中國交易所交易的股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。